Fiserv's weak results and guidance cut send stock plunging over 40%, prompting a leadership overhaul and a plan to restore growth and investor confidence.
Pfizer sues Novo Nordisk to block its $8.5-$9B bid for Metsera, alleging antitrust violations and a 'kill' strategy to preserve dominance in GLP-1 obesity drugs.
Fiserv's weak results and guidance cut send stock plunging over 40%, prompting a leadership overhaul and a plan to restore growth and investor confidence.
Pfizer sues Novo Nordisk to block its $8.5-$9B bid for Metsera, alleging antitrust violations and a 'kill' strategy to preserve dominance in GLP-1 obesity drugs.